Low-dose radiation exposure and atherosclerosis in ApoE⁻/⁻ mice. 2011

R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
Radiological Protection Research and Instrumentation Branch, Atomic Energy of Canada, Chalk River, Ontario, Canada. mitchelr@aecl.ca

The hypothesis that single low-dose exposures (0.025-0.5 Gy) to low-LET radiation given at either high (about 150 mGy/min) or low (1 mGy/min) dose rate would promote aortic atherosclerosis was tested in female C57BL/6J mice genetically predisposed to this disease (ApoE⁻/⁻). Mice were exposed either at an early stage of disease (2 months of age) and examined 3 or 6 months later or at a late stage of disease (8 months of age) and examined 2 or 4 months later. Changes in aortic lesion frequency, size and severity as well as total serum cholesterol levels and the uptake of lesion lipids by lesion-associated macrophages were assessed. Statistically significant changes in each of these measures were observed, depending on dose, dose rate and disease stage. In all cases, the results were distinctly non-linear with dose, with maximum effects tending to occur at 25 or 50 mGy. In general, low doses given at low dose rate during either early- or late-stage disease were protective, slowing the progression of the disease by one or more of these measures. Most effects appeared and persisted for months after the single exposures, but some were ultimately transitory. In contrast to exposure at low dose rate, high-dose-rate exposure during early-stage disease produced both protective and detrimental effects, suggesting that low doses may influence this disease by more than one mechanism and that dose rate is an important parameter. These results contrast with the known, generally detrimental effects of high doses on the progression of this disease in the same mice and in humans, suggesting that a linear extrapolation of the known increased risk from high doses to low doses is not appropriate.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses
D050356 Lipid Metabolism Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS. Metabolism, Lipid
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
January 2019, Journal of vascular research,
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
January 2012, Journal of atherosclerosis and thrombosis,
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
March 1990, Science (New York, N.Y.),
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
April 2011, Atherosclerosis,
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
November 2013, Toxicology letters,
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
October 2015, Oncotarget,
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
May 2009, Atherosclerosis,
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
July 2012, Japanese journal of clinical oncology,
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
January 2022, Journal of immunology research,
R E J Mitchel, and M Hasu, and M Bugden, and H Wyatt, and M P Little, and A Gola, and G Hildebrandt, and N D Priest, and S C Whitman
August 2000, Arteriosclerosis, thrombosis, and vascular biology,
Copied contents to your clipboard!